bpc 157 + tb 500 BPC-157 TB-500 Blend | Public COA BPC-157 + TB-500 Blend Peptide

Healthier skin, hair, and nails

(2022) 8:eabn1382

Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy

For people who are legitimately on these medications at full-dose , Wegovy and Zepbound allow dose pauses and slower steps for tolerability, while keeping the maintenance target in sight

Catching it early matters, because nerve damage that builds up over a long time doesnt always fully reverse, even after B12 levels come back up